BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 15703810)

  • 1. Identification of circulating prostate cancer cells: a challenge to the clinical implementation of molecular biology (review).
    Schamhart DH; Maiazza R; Kurth KH
    Int J Oncol; 2005 Mar; 26(3):565-77. PubMed ID: 15703810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly specific detection of prostate-specific antigen-positive cells in the blood of patients with prostate cancer or benign prostatic hyperplasia, using a real-time reverse-transcription-polymerase chain reaction method with improved sensitivity.
    Barbero G; Destefanis P; Procida S; Mandili G; Ulliers D; Ceruti C; Fiori C; Maule MM; Fontana D; Giribaldi G; Turrini F
    BJU Int; 2008 Dec; 102(11):1566-72. PubMed ID: 18549428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The detection and isolation of viable prostate-specific antigen positive epithelial cells by enrichment: a comparison to standard prostate-specific antigen reverse transcriptase polymerase chain reaction and its clinical relevance in prostate cancer.
    Pfitzenmaier J; Ellis WJ; Hawley S; Arfman EW; Klein JR; Lange PH; Vessella RL
    Urol Oncol; 2007; 25(3):214-20. PubMed ID: 17483018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of nested RT-PCR of prostate-specific membrane antigen in blood cells: implications for the detection of haematogenous neoplastic cells in patients with prostate adenocarcinoma.
    Lucotte G; Mercier G; Burckel A
    Mol Cell Probes; 1998 Dec; 12(6):421-5. PubMed ID: 9843660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analytical variables of reverse transcription-polymerase chain reaction-based detection of disseminated prostate cancer cells.
    Zippelius A; Lutterbüse R; Riethmüller G; Pantel K
    Clin Cancer Res; 2000 Jul; 6(7):2741-50. PubMed ID: 10914719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prostate-specific membrane antigen. A new sensitive molecular indicator in metastasizing prostatic cancer].
    Kippersund JT; Haukeland B; Lilleeng BF; Daehlin L; Haukaas S; Høisaeter PA; Ogreid D
    Tidsskr Nor Laegeforen; 1995 Nov; 115(29):3612-5. PubMed ID: 8539714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative real-time reverse transcription: polymerase chain reaction of prostate-specific antigen (PSA) for detection of circulating prostatic cells in patients with clinically localized prostate cancer.
    Llanes L; Ferruelo A; Luján M; Pascual C; García-Mediero JM; Berenguer A
    Prostate Cancer Prostatic Dis; 2005; 8(3):248-52. PubMed ID: 15897916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does the molecular staging in pelvic lymph nodes improve the detection of relevant prostate cancer metastases? An assessment after 6 years.
    Schostak M; Krause H; Miller K; Schrader M; Kempkensteffen C; Kollermann J
    BJU Int; 2007 Jun; 99(6):1409-14. PubMed ID: 17428244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Detection of micrometastases and circulating tumour cells using molecular biology technics in solid tumours].
    Schleiermacher G; Delattre O
    Bull Cancer; 2001 Jun; 88(6):561-70. PubMed ID: 11459702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen mRNA and protein levels in laser microdissected cells of human prostate measured by real-time reverse transcriptase-quantitative polymerase chain reaction and immuno-quantitative polymerase chain reaction.
    Pinzani P; Lind K; Malentacchi F; Nesi G; Salvianti F; Villari D; Kubista M; Pazzagli M; Orlando C
    Hum Pathol; 2008 Oct; 39(10):1474-82. PubMed ID: 18619642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reverse transcriptase-polymerase chain reaction and immunohistochemical studies for detection of prostate stem cell antigen expression in prostate cancer: potential value in molecular staging of prostate cancer.
    Joung JY; Yang SO; Jeong IG; Han KS; Seo HK; Chung J; Park WS; Lee KH
    Int J Urol; 2007 Jul; 14(7):635-43. PubMed ID: 17645609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between CD8+ T cells specific for prostate-specific antigen and level of disease in patients with prostate cancer.
    Elkord E; Rowbottom AW; Kynaston H; Williams PE
    Clin Immunol; 2006 Jul; 120(1):91-8. PubMed ID: 16458609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reverse transcriptase PCR and staging prostate cancer.
    Robbins DJ; Velez LF; Burczak JD
    Clin Lab Sci; 1997; 10(5):265-71. PubMed ID: 10177203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationships between reverse transcriptase-polymerase chain reaction for prostate specific antigen, survival, and various prognostic laboratory factors in patients with hormone refractory prostate cancer.
    Gandhok NK; Looney S; Koochekpour S; Sartor O
    Urol Oncol; 2005; 23(3):163-7. PubMed ID: 15907715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy.
    Ross RW; Manola J; Hennessy K; Galsky M; Scher H; Small E; Kelly WK; Kantoff PW
    Clin Cancer Res; 2005 Jul; 11(14):5195-8. PubMed ID: 16033836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Detection of urine DD3/PSA mRNA ratio by duplex TaqMan RT-PCR assay and evolution of its primary application].
    Chen FP; Chen LL; Shen M; Chen W; Tao ZH; Wu XL; Hu YP; Li CD; Chen ZG; Chen XD
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(4):261-4. PubMed ID: 18361839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher expression of the androgen-regulated gene PSA/HK3 mRNA in prostate cancer tissues predicts biochemical recurrence-free survival.
    Sterbis JR; Gao C; Furusato B; Chen Y; Shaheduzzaman S; Ravindranath L; Osborn DJ; Rosner IL; Dobi A; McLeod DG; Sesterhenn IA; Srivastava S; Cullen J; Petrovics G
    Clin Cancer Res; 2008 Feb; 14(3):758-63. PubMed ID: 18245536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multigene methylation analysis for detection and staging of prostate cancer.
    Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
    Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular cancer phenotype in normal prostate tissue.
    Schlomm T; Hellwinkel OJ; Buness A; Ruschhaupt M; Lübke AM; Chun FK; Simon R; Budäus L; Erbersdobler A; Graefen M; Huland H; Poustka A; Sültmann H
    Eur Urol; 2009 Apr; 55(4):885-90. PubMed ID: 18501497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.